Clinical trials: Multi-System-Atrophy
Multiple Sclerosis, Sarcopenia
Investigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters
This cross-sectional observational study aims to determine the prevalence of sarcopenia and dynapenia across disability stages in patients with multiple sclerosis (MS) and investigate their associations with clinical and…
- Conditions
- Multiple Sclerosis, Sarcopenia, Dynapenia
- Trial name
- MS-Sarcopenia (NCT07842731)
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Atılım University
Parkinson Disease, Progressive Supranuclear Palsy(PSP)
Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely
This is an observational longitudinal study in 4 cohorts of patients with Parkinsonian syndromes, who are visiting the Movement Disorders outpatient clinics.
- Conditions
- Parkinson Disease, Progressive Supranuclear Palsy(PSP), Multiple System Atrophy
- Trial name
- PARATROOPER (NCT06597071)
- Testing
- NeuraLight PD, NeuraLight PSP, NeuraLight MSA
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NeuraLight
Duchenne Muscular Dystrophy
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy
Study to characterize the single-state and steady-state dosing of oral deflazacort in pediatric and adolescents subjects.
- Trial name
- NCT02251600
- Testing
- Deflazacort
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- PTC Therapeutics
Multiple Sclerosis
Thalamic Nuclei Volumes in Multiple Sclerosis
The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and due to direct damages that could be partly…
- Trial name
- THALNUC-MS (NCT05002764)
- Where
- France
- Volunteers
- 2,000 people
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy
Insulin Resistance in Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions.
- Trial name
- IRAMS (NCT04250493)
- Testing
- Homeostasis Model Assessment of insulin resistance (HOMA), MOntreal Cognitive Assessment (MoCA), Clinical characteristics of AMS patients
- Where
- France
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Facioscapulohumeral Muscular Dystrophy (FSHD)
A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SFL-0821 in adult patients with Facioscapulohumeral Muscular Dystrophy (FSHD)
- Trial name
- NCT07798609
- Testing
- SFL-0821 for injection
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 90 people
- Sponsor
- Soufflé Therapeutics, Inc.
Diabetes Mellitus, Type 1, Monogenic Diabetes
Monogenic Diabetes Misdiagnosed as Type 1
The study has two aims: 1. To (1a) determine the frequency of monogenic diabetes misdiagnosed as type 1 diabetes (T1D) and (2) to define an algorithm for case selection. 2.
- Conditions
- Diabetes Mellitus, Type 1, Monogenic Diabetes, Neonatal Diabetes, Maturity-onset Diabetes in the Young (MODY)
- Trial name
- ADDAM (NCT03988764)
- Testing
- None AHT
- Where
- Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Protein Deficiency, Training Group, Sensitivity
Effects of a Multi-Ingredient Pre-Workout Supplement on Body Composition, Performance, Muscular Properties, and Wellbeing in Adults.
The investigation will be conducted as a double blinded, randomized, parallel between treatment conditions comparison design with two different groups ingesting a different supplement each one.
- Conditions
- Protein Deficiency, Training Group, Sensitivity, Fatigue, Muscular Atrophy
- Trial name
- NCT05769088
- Testing
- Ingestion of a Pre-Workout Supplement, Ingestion of a Maltodextrin Supplement
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Joel Puente
Spinal Cord Injuries, Autonomic Dysreflexia
Spinal Cord Stimulation and Autonomic Response in People With SCI.
Despite being studied less than half as frequently, autonomic dysfunction is a greater priority than walking again in spinal cord injury.
- Conditions
- Spinal Cord Injuries, Autonomic Dysreflexia, Orthostatic Hypotension, Dysautonomic
- Trial name
- NCT03924388
- Testing
- Epidural spinal cord stimulation, Trnascutaneous electrical spinal cord stimulation.
- Where
- 2 sites in Canada
- Volunteers
- 46 people
- Sponsor
- University of Calgary
REM Sleep Behavior Disorder, Parkinson Disease
North American Prodromal Synucleinopathy Consortium
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
- Conditions
- REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies
- Trial name
- NAPS (NCT03623672)
- Where
- 10 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Washington University School of Medicine
Cerebrovascular Accident, Post-polio Syndrome
Nomad P-KAFO Study
The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk.
- Conditions
- Cerebrovascular Accident, Post-polio Syndrome, Spinal Cord Injuries, Multiple Sclerosis
- Trial name
- NCT05644522
- Testing
- Indego Nomad® Powered Knee-Ankle-Foot Orthosis (P-KAFO) (Parker Hannifin Corp., Cleveland, OH)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Shirley Ryan AbilityLab
Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant
Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients
This study will comprise of two phases, an observational phase and a treatment phase. In the observational phase the specific aims are: 1.
- Conditions
- Multiple System Atrophy, Multiple System Atrophy, Cerebellar Variant, Multiple System Atrophy, Parkinson Variant (Disorder), Multiple System Atrophy (MSA) With Orthostatic Hypotension
- Trial name
- NCT04616456
- Testing
- [F-18]PBR06, Verdiperstat
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Brigham and Women's Hospital
Hereditary Ataxia, Multiple Sclerosis
Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
Cerebellar disorders are often disabling and symptomatic therapies are limited to few options that are partially effective. It seems therefore appropriate to search for additional approaches.
- Conditions
- Hereditary Ataxia, Multiple Sclerosis, Cerebellar Ataxia
- Trial name
- NCT00202397
- Testing
- Riluzole
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- S. Andrea Hospital
Muscular Dystrophy, Duchenne
A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy
This is a multicenter, double blind, placebo controlled, multiple dose study to examine the safety and efficacy of MNK-1411 in male subjects 4 to 8 years of age (inclusive) with Duchenne Muscular Dystrophy (DMD).
- Trial name
- BRAVE (NCT03400852)
- Testing
- MNK-1411
- Where
- 16 sites in United States, Bulgaria and 6 more
- Volunteers
- 44 people
- Sponsor
- Mallinckrodt ARD LLC
Multiple System Atrophy
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
- Trial name
- MASCOT (NCT06706622)
- Testing
- Amlenetug
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 401 people
- Sponsor
- H. Lundbeck A/S
Muscular Dystrophy, Duchenne
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
- Trial name
- NCT02286947
- Testing
- Eteplirsen
- Where
- 9 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sarepta Therapeutics, Inc.
Multiple System Atrophy (MSA)
Oligomeric Alpha-synuclein in Multiple System Atrophy
The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF)…
- Trial name
- BIOAMS (NCT01485549)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bordeaux
Multiple System Atrophy
Expansion Study of ALT001 in Patients With Multiple System Atrophy
This is an open-label, single-center, prospective, single-arm clinical study. The primary objective of this study is to evaluate the safety, tolerability, and preliminary efficacy of ALT001 in the treatment of patients with…
- Trial name
- ALT001 in MSA (NCT07476352)
- Testing
- ALT001
- Where
- China
- Volunteers
- 60 people
- Sponsor
- yilong Wang
Neuromuscular Diseases (NMD), Charcot Marie Tooth Disease (CMT)
Personalized Training for People With Rare Neuromuscular Disorders
The goal of this study is to investigate the effects of personalized exercise treatment on dynamic balance and physical function in comparison with regular follow-up in adults with rare-neuromuscular disorders…
- Conditions
- Neuromuscular Diseases (NMD), Charcot Marie Tooth Disease (CMT), Facioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy Type 1 (DM1)
- Trial name
- PETRA-NMD (NCT06708468)
- Testing
- Exercise, Usual Care
- Where
- 5 sites in Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital
Multiple Sclerosis, Tomography, Optical Coherence
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
- Conditions
- Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
- Trial name
- NCT06167642
- Testing
- Ofatumumab
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University